187 related articles for article (PubMed ID: 36991352)
1. Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity.
Gajofatto A; Cardobi N; Gobbin F; Calabrese M; Turatti M; Benedetti MD
BMC Neurol; 2023 Mar; 23(1):128. PubMed ID: 36991352
[TBL] [Abstract][Full Text] [Related]
2. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
[TBL] [Abstract][Full Text] [Related]
3. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
Paul F; Silván CV
Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
[TBL] [Abstract][Full Text] [Related]
4. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
[TBL] [Abstract][Full Text] [Related]
6. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
[TBL] [Abstract][Full Text] [Related]
7. Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.
De Blasiis P; Siani MF; Fullin A; Sansone M; Melone MAB; Sampaolo S; Signoriello E; Lus G
Mult Scler Relat Disord; 2021 Jun; 51():102805. PubMed ID: 33862313
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
Haupts MR; Essner U; Mäurer M
Neurodegener Dis Manag; 2024 Feb; 14(1):11-20. PubMed ID: 38318862
[TBL] [Abstract][Full Text] [Related]
9. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
Chan A; Silván CV
Neurodegener Dis Manag; 2022 Jun; 12(3):141-154. PubMed ID: 35377770
[TBL] [Abstract][Full Text] [Related]
12. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
13. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis.
Gajofatto A
Mult Scler Relat Disord; 2016 Jul; 8():64-5. PubMed ID: 27456876
[TBL] [Abstract][Full Text] [Related]
14. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Riva N; Mora G; Sorarù G; Lunetta C; Ferraro OE; Falzone Y; Leocani L; Fazio R; Comola M; Comi G;
Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
[TBL] [Abstract][Full Text] [Related]
16. Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.
Alessandria G; Meli R; Infante MT; Vestito L; Capello E; Bandini F
Clin Neurol Neurosurg; 2020 Sep; 196():105990. PubMed ID: 32526487
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
Nicholas J; Lublin F; Klineova S; Berwaerts J; Chinnapongse R; Checketts D; Javaid S; Steinerman JR
Mult Scler Relat Disord; 2023 Jul; 75():104745. PubMed ID: 37209500
[TBL] [Abstract][Full Text] [Related]
18. Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
Conte A; Vila Silván C
Neurodegener Dis; 2021; 21(3-4):55-62. PubMed ID: 34731865
[TBL] [Abstract][Full Text] [Related]
19. The use of medical-grade cannabis in patients non-responders to Nabiximols.
Saccà F; Pane C; Carotenuto A; Massarelli M; Lanzillo R; Florio EB; Brescia Morra V
J Neurol Sci; 2016 Sep; 368():349-51. PubMed ID: 27538663
[No Abstract] [Full Text] [Related]
20. Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.
Kleiner D; Horváth IL; Bunduc S; Gergő D; Lugosi K; Fehérvári P; Hegyi P; Csupor D
Curr Neuropharmacol; 2023; 21(12):2505-2515. PubMed ID: 37519000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
